ABUJA, Nigeria – UK oncology diagnostics firm Digistain has partnered with Numelec Africa Holdings (NAH) to introduce its pioneering DNA-based breast cancer risk profiling test in Nigeria.
The test, developed at Imperial College London, predicts the likelihood of cancer recurrence with up to 99 per cent accuracy.
It enables oncologists to decide whether chemotherapy is necessary, cutting costs and sparing patients unnecessary treatment.
CEO, Digistain, Hemmel Amrania called it a milestone. “This partnership extends our AI-enabled diagnostic platform beyond Europe, empowering Nigerian oncologists with rapid, affordable cancer diagnostics,” he said.
Numelec Africa Chairman Ese Owie stressed its impact. “By introducing this technology, we are setting a new standard for precision oncology in Africa, reducing costs and improving access,” he noted.
The World Health Organisation says breast cancer accounts for 23 per cent of new cancer cases and 18 per cent of cancer deaths in Nigeria. Analysts say Digistain’s entry could transform cancer care in West Africa.
